Dana Investment Advisors Inc. Has $6.48 Million Holdings in Regeneron Pharmaceuticals, Inc. $REGN

Dana Investment Advisors Inc. grew its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 58.0% during the 4th quarter, HoldingsChannel.com reports. The firm owned 8,395 shares of the biopharmaceutical company’s stock after acquiring an additional 3,082 shares during the quarter. Dana Investment Advisors Inc.’s holdings in Regeneron Pharmaceuticals were worth $6,480,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. WPG Advisers LLC increased its position in Regeneron Pharmaceuticals by 312.5% in the 4th quarter. WPG Advisers LLC now owns 33 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 25 shares during the last quarter. Board of the Pension Protection Fund acquired a new position in Regeneron Pharmaceuticals in the 4th quarter worth about $31,000. Torren Management LLC acquired a new position in Regeneron Pharmaceuticals in the 4th quarter worth about $38,000. FNY Investment Advisers LLC acquired a new position in Regeneron Pharmaceuticals in the 4th quarter worth about $38,000. Finally, Oakworth Capital Inc. increased its position in Regeneron Pharmaceuticals by 124.0% in the 4th quarter. Oakworth Capital Inc. now owns 56 shares of the biopharmaceutical company’s stock worth $43,000 after purchasing an additional 31 shares during the last quarter. 83.31% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Regeneron Pharmaceuticals

In other news, Director Huda Y. Zoghbi sold 1,638 shares of the stock in a transaction dated Thursday, February 19th. The stock was sold at an average price of $781.33, for a total transaction of $1,279,818.54. Following the transaction, the director owned 1,703 shares of the company’s stock, valued at approximately $1,330,604.99. This represents a 49.03% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Arthur F. Ryan sold 100 shares of the stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $705.24, for a total value of $70,524.00. Following the sale, the director owned 17,503 shares of the company’s stock, valued at approximately $12,343,815.72. The trade was a 0.57% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 6.97% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on REGN shares. Wells Fargo & Company dropped their target price on Regeneron Pharmaceuticals from $825.00 to $800.00 and set an “equal weight” rating on the stock in a research report on Thursday, April 30th. TD Cowen upped their target price on Regeneron Pharmaceuticals from $880.00 to $960.00 and gave the stock a “buy” rating in a research report on Thursday, April 23rd. Evercore upped their target price on Regeneron Pharmaceuticals from $750.00 to $875.00 and gave the stock an “outperform” rating in a research report on Thursday, January 22nd. Oppenheimer reaffirmed an “outperform” rating and issued a $865.00 target price (up from $750.00) on shares of Regeneron Pharmaceuticals in a research report on Monday, February 2nd. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a research report on Friday, March 27th. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and eight have issued a Hold rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $826.59.

Regeneron Pharmaceuticals Stock Performance

Shares of NASDAQ REGN opened at $698.25 on Friday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.96 and a current ratio of 3.57. The firm has a market cap of $73.82 billion, a price-to-earnings ratio of 17.01, a P/E/G ratio of 1.55 and a beta of 0.30. The business’s 50-day simple moving average is $744.69 and its 200-day simple moving average is $744.97. Regeneron Pharmaceuticals, Inc. has a 52 week low of $476.49 and a 52 week high of $821.11.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Wednesday, April 29th. The biopharmaceutical company reported $9.47 EPS for the quarter, beating analysts’ consensus estimates of $8.91 by $0.56. The business had revenue of $3.61 billion for the quarter, compared to analyst estimates of $3.48 billion. Regeneron Pharmaceuticals had a return on equity of 13.16% and a net margin of 29.65%.The firm’s revenue for the quarter was up 19.0% on a year-over-year basis. During the same quarter in the prior year, the firm posted $8.22 EPS. As a group, equities research analysts expect that Regeneron Pharmaceuticals, Inc. will post 37.1 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, June 4th. Stockholders of record on Wednesday, May 20th will be issued a dividend of $0.94 per share. The ex-dividend date of this dividend is Wednesday, May 20th. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.5%. Regeneron Pharmaceuticals’s dividend payout ratio is currently 9.16%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.